STEM-Parkinson's Disease

ID#: NCT04797611

Age: 18 - 85 years

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: May 19, 2022

End Date: December 01, 2023

Contact Information:
Kara Richardson
(984) 884-1020
Jemica Warren
(984) 884-5230
Summary: This is a double-blinded, controlled, randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Eligibility:

Inclusion Criteria:

- Adult participants (aged 18

- 85 years inclusive)

- Diagnosed with Parkinson's disease according to the UK Brain Bank Criteria

- Demonstrates a positive response to oral anti-Parkinsonian medications (i.e. dopamine replacement therapies) and treated with these medications for minimum of one year prior to the screening visit

- Report limitation to activities of daily living (e.g., writing, walking, bathing, dressing, eating, toileting, etc.)

- Able and willing to consent to participate in the study.

- Willing and able to comply with study requirements.

- Anticipate being able to remain on a stable regimen of medications used for the management of PD motor and non-motor symptoms and not to introduce new medications used to treat symptoms associated with PD during the trial.

- Have at minimum a moderate burden of non-motor symptoms associated with Parkinson's disease

- Have a study partner (defined as someone who sees the participant for more than one hour a day, 3 times per week) that is willing to consent and participate in the trial.

- Have capabilities to use and access smartphones and or tablets for the collection of some study data.

- Must be willing to answer questions related to sexual interest, arousal, and performance in an interview with study staff.

Exclusion Criteria:

- Participant anticipates being unable to attend all visits and complete all study activities.

- Women of child-bearing potential who are pregnant or plan to become pregnant during the course of the study trial. Women of child-bearing potential , who are not abstinent or exclusively in same sex relationships must:

1. Test negative for pregnancy as indicated by a negative urine pregnancy test

2. Agree to use an approved contraception method for the entirety of the trial

- Have a history or prior diagnosis of dementia or evidence of dementia at study screen.

- Have experienced a myocardial infarction, angina, or stroke within the past 12 months, or a transient ischemic attack within the past 6 months.

- Are receiving deep brain stimulation therapy.

- Are treated with a pump for continuous delivery of dopamine replacement medication.

- Use apomorphine rescue.

- Have received MRI guided high intensity focused ultrasound within the past 12 months.

- Experience frequent falls.

- Work night shifts

- Use a hearing aid that is implanted or that cannot be easily removed and replaced.

- Have a cochlear implant.

- Have chronic (>3 months) tinnitus.

- Have previously been diagnosed with traumatic brain injury with ongoing sequalae.

- Have been diagnosed with a co-morbid neurological disorder that may present with symptoms overlapping with PD (e.g., stroke, brain tumor, epilepsy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, atypical Parkinsonism or aneurysm)

- Have unresolved complications from a previous surgical procedure at the baseline visits, such as swelling or persistent pain, that requires medical intervention.

- Have active ear infections, or other significant ear problems.

- Have a recent history of frequent ear infections (≥ 1 per year over the past two years)

- Are currently enrolled or have participated in another interventional clinical trial within the last 30 days.

- Have had eye surgery within the previous three months or ear surgery within the previous six months.

- Have planned surgery scheduled to occur during the study that requires sedation and/or would typically be followed with a prescription for pain management.